Your browser doesn't support javascript.
loading
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Bozina, Nada; Sporis, Ivana Susak; Domjanovic, Iva Klarica; Ganoci, Lana; Simicevic, Livija; Lovric, Mila; Romic, Zrinka Colak; Gadze, Zeljka Petelin; Trkulja, Vladimir.
Affiliation
  • Bozina N; Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia.
  • Sporis IS; Department of Neurology, University Hospital Dubrava, Zagreb, Croatia.
  • Domjanovic IK; Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University, Osijek, Croatia.
  • Ganoci L; Croatian Agency for Medicinal Products and Medical Devices, Zagreb, Croatia.
  • Simicevic L; Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.
  • Lovric M; Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.
  • Romic ZC; Analytical Toxicology and Pharmacology Division, Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia.
  • Gadze ZP; Department of Neurology, University Hospital Dubrava, Zagreb, Croatia.
  • Trkulja V; Department of Neurology, University Hospital Center Zagreb, Zagreb, Croatia.
Eur J Clin Pharmacol ; 79(8): 1117-1129, 2023 Aug.
Article in En | MEDLINE | ID: mdl-37340142
ABSTRACT

PURPOSE:

To estimate whether epilepsy patients with variant UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) alleles differ from their wild-type (wt) peers in exposure to lamotrigine.

METHODS:

Consecutive adults on lamotrigine monotherapy or lamotrigine + valproate co-treatment undergoing routine therapeutic drug monitoring, otherwise generally healthy and free of interacting drugs, were genotyped for UGT2B7 -161C > T and UGT1A4*3 c.142 T > G. Heterozygous, variant homozygous, or combined heterozygous/variant homozygous subjects were compared to their wt controls for dose-adjusted lamotrigine troughs with adjustment for age, sex, body weight, rs7668258/rs2011425, polymorphisms of efflux transporter proteins ABCG2 c.421C > A (rs2231142) and ABCB1 1236C > T (rs1128503), and level of exposure to valproate using covariate entropy balancing.

RESULTS:

Of the 471 included patients, 328 (69.6%) were on monotherapy and 143 were co-treated with valproate. Dose-adjusted lamotrigine troughs in UGT2B7 -161C > T heterozygous (CT, n = 237) or variant homozygous (TT, n = 115) subjects were closely similar to those in their wt controls (CC, n = 119) geometric means ratios (GMRs) (frequentist and Bayes) 1.00 (95%CI 0.86-1.16) and 1.00 (95%CrI 0.83-1.22) for CT vs. CC; and 0.97 (0.81-1.17) and 0.97 (0.80-1.20) for TT vs. CC subjects. Lamotrigine troughs were also closely similar in UGT1A4*3 c.142 T > G variant carriers (n = 106 102 TG + 4 GG subjects) and wt controls (TT, n = 365) GMR = 0.95 (0.81-1.12) frequentist, 0.96 (0.80-1.16) Bayes. GMRs for variant carriers vs. wt controls were around unity also at different levels of exposure to valproate.

CONCLUSION:

Dose-adjusted lamotrigine troughs in epilepsy patients with variant UGT2B7 -161C > T or UGT1A4*3 c.142 T > G alleles are equivalent to those in their respective wt peers.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Valproic Acid / Epilepsy Limits: Adult / Humans Language: En Journal: Eur J Clin Pharmacol Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Valproic Acid / Epilepsy Limits: Adult / Humans Language: En Journal: Eur J Clin Pharmacol Year: 2023 Document type: Article Affiliation country:
...